STING1 and neoplasm: (3) Biomarker Development: Identify predictive biomarkers (e.g., tumor STING pathway activation status, baseline CD8+ T cell infiltration, or chemokine profiles) to help identify patient subgroups most likely to benefit from PTE-based therapies.